Today's Pre-Open Stock Movers

Kensington Capital Acquisition (NYSE: KCAC) +50%; QuantumScape, the 10-year-old Silicon Valley battery startup backed by Volkswagen AG , said on Thursday it plans to go public through a reverse merger with Kensington Capital Acquisition Corp with an enterprise value of $3.3 billion.

FibroGen (NASDAQ: FGEN) +15%; rises after Akebia safety data miss.

Five Below (NASDAQ: FIVE) +8%; reported Q2 EPS of $0.53, $0.39 better than the analyst estimate of $0.14. Revenue for the quarter came in at $426.1 million versus the consensus estimate of $405.83 million.

ADMA Biologics (NASDAQ: ADMA) +7.5%; announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma. ImmunoRank™ was developed in collaboration with Leinco Technologies, Inc. (“Leinco”). ImmunoRank is intended for use as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, and specifically for the detection of circulating SARS-CoV-2 neutralizing antibodies in human plasma of all immune globulin classes.

Novavax (NASDAQ: NVAX) +6%; announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX‑CoV2373, its COVID‑19 vaccine candidate adjuvanted with Matrix‑M™, in healthy adults 18-59 years of age. The publication offers further detail on the previously announced results, in which NVX‑CoV2373 demonstrated a reassuring safety and reactogenicity profile and induced robust antibody responses numerically superior to that seen in human convalescent sera.

Akebia Therapeutics (NASDAQ: AKBA) -70%; Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two PRO2TECT studies, demonstrating non-inferiority (NI) to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is the composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke across both PRO2TECT studies.

Zuora, Inc. (NYSE: ZUO) -26.6%; reported Q2 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $75 million versus the consensus estimate of $73.47 million. GUIDANCE: Zuora, Inc. sees Q3 2021 EPS of ($0.05)-($0.04), versus the consensus of ($0.05). Zuora, Inc. sees Q3 2021 revenue of $73-75 million, versus the consensus of $75.6 million.

PagerDuty, Inc. (NYSE: PD) -24%; reported Q2 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $50.7 million versus the consensus estimate of $50.7 million. PagerDuty, Inc. sees Q3 2021 EPS of ($0.11)-($0.10), versus the consensus of ($0.09). PagerDuty, Inc. sees Q3 2021 revenue of $52-53 million, versus the consensus of $52.56 million.

Ciena (NYSE: CIEN) -17%; reported Q3 EPS of $1.06, $0.24 better than the analyst estimate of $0.82. Revenue for the quarter came in at $976.7 million versus the consensus estimate of $971.77 million.

CrowdStrike Holdings Inc. (NASDAQ: CRWD) -10%; reported Q2 EPS of $0.03, $0.04 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $199 million versus the consensus estimate of $188.54 million. GUIDANCE: CrowdStrike Holdings Inc. sees Q3 2021 EPS of ($0.01)-$0.00, versus the consensus of ($0.05). CrowdStrike Holdings Inc. sees Q3 2021 revenue of $210.6-215 million, versus the consensus of $195.75 million.

Rocket Companies (NYSE: RKT) -10%; reported Q2 revenue for the quarter of $5.04 billion, may not compare versus the consensus estimate of $3.75 billion. Third Quarter Outlook Net rate lock volume of between $93 billion and $98 billion, which would represent an increase of 98% to 108% compared to $47.0 billion in the third quarter of 2019.

Tesla (NASDAQ: TSLA) -6.75%, falling for the third session after announcing a $5 billion stock offering.